Globus Medical, Inc.

Globus Medical, Inc. Earnings Recaps

GMED Health Care 3 recaps
Next earnings: February 23, 2027 (estimated) · full calendar
Q3 2026 Nov 8, 2026

Globus Medical fell 12.8% after earnings, as investors likely focused on near-flat total revenue, only 2% U.S. Spine growth, and delayed product launches and production issues that management said are limiting growth until 2027. Nevro’s 25.7% decline added to the drag, despite growth in enabling technologies and higher EPS.

Key takeaways
  • Q3 revenue was $763.7 million, down 0.7% reported and 0.5% in constant currency. Base business excluding Nevro grew 3% to $690 million; Nevro revenue fell 25.7% to $73.7 million.
  • U.S. Spine grew 2%. Management attributed the slowdown to delayed product launches, lingering production issues and lower contributions from competitive recruiting; it expects launches to support growth entering 2027.
  • Enabling Technologies revenue rose 24% to $34.9 million. EGPS and eHub units deployed, including sold, leased or rented units, increased 73% year over year.
  • Non-GAAP EPS was $1.23, up 4% year over year, and free cash flow reached a record $225 million despite a 13% increase in capital expenditures.
  • The company repurchased 1.9 million shares for $143 million. SCRIPT implants and rods are available; the XLIF Prone Solution and 2-Blade Retractor are expected later this quarter, while EIQ is in final introduction stages and is expected to contribute meaningfully in 2027 and beyond.
Q1 2026 May 9, 2026

Shares declined 12.6% as investors reacted negatively to a cautious revenue mix shift and softer growth in Enabling Technologies, signaling concerns over decelerating upfront sales and a more conservative capital equipment approach.

Key takeaways
  • Total Q1 revenue rose 27% to $759.9 million, with base business growth at 13.2%, led by a resilient 10% increase in U.S. Spine sales.
  • Enabling Technologies revenue grew 21% to $26.9 million but showed a sequential step down; management highlighted a shift from upfront sales to leases and rentals, reducing near-term revenue recognition.
  • International Spine sales increased 16.4% reported (9.8% constant currency), benefiting from easing prior-year supply chain disruptions primarily in EMEA and Latin America.
  • The recurring revenue strategy focusing on implant pull-through and service was reiterated, but execution risks remain amid rising competitive pressures in robotics and evolving capital acquisition models.
  • Despite strong free cash flow and margin expansion commentary, the market appears concerned about slower near-term visibility and the impact of a more cautious guidance posture embedded in the revenue mix.
Q3 2025 Nov 8, 2025

Globus Medical reported a robust Q3 2025, with sales increasing 22.9% to $769 million and non-GAAP EPS jumping 42.6% to $1.18, driven by strong growth in both the U.S. and international spine markets.

Key takeaways
  • Base business revenue rose to $669.8 million, with an adjusted EBITDA margin improvement of 435 basis points to 35.3%.
  • Free cash flow reached a record $213.9 million, underlining operational efficiency and strong cash generation.
  • The U.S. Spine segment grew by 9.6%, maintaining positive momentum with 32 consecutive weeks of growth.
  • The recently acquired Nevro business contributed $99.3 million in revenue, enhancing overall business expansion.
  • Strategic share repurchases totaled $40 million during the quarter, reflecting confidence in long-term growth and shareholder value.